drugset / Trial / NCT05269706
Investigation of the Pharmacokinetic Profile of CBD
RandomizedCrossoverTriple-blindOther
Summary
The goal of the current study is to evaluate the bioavailability of CBD in normal healthy Individuals. This is an open cross-overdesign study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.
Timeline
- Start
- 2022-05-18
- Primary completion
- 2023-02-16
- Completion
- 2023-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 200 mg | — |
| Subject | Cannabidiol | Other / unclassified | 400 mg | — |